Angina Pectoris Treatment Market By Drug Type (Antiplatelet agents, Beta-adrenergic blocking agents, Calcium channel blockers, Short & Long – acting Nitroglycerines, Angiotensin-converting enzyme inhibitors, Anti-ischemic agents) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

This report on global angina pectoris treatment market studies various drugs used for treatment of angina pectoris along with pipeline analysis of upcoming potential drugs. Angina is chest pain due to transient myocardial ischaemia, which usually occurs with physical activity or emotional stress, in the United States 10.2 million are estimated to experience angina with approximately 500,000 new cases occurring each year. Thus, drug pipeline of angina pectoris treatment market comprises potential drugs which are specific and fast in therapeutic action. 

For the purpose of this study, the various drug classes studied include antiplatelet agents, beta-adrenergic blocking agents, calcium channel blockers, short & long – acting nitroglycerines angiotensin-converting enzyme inhibitors and anti-ischemic agents. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

The pipeline analysis for angina pectoris treatment market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are Dantonic/T89 (Tasly Pharmaceuticals, Inc.), RANCAD (TSH Biopharm Corporation Limited), Cilostazol (Korea Otsuka Pharmaceutical Co.,Ltd.), Bococizumab (Pfizer, Inc.), Ticagrelor (J.M. ten Berg/ Astra Zeneca plc), Auto-CD34+ cells (Baxalta US Inc.) and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

The geographic segmentation of the global angina pectoris market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

Drug Class Segmentation Analysis

Angina pectoris is a temporary chest pain or discomfort as a result of decreased blood flow to the heart muscle which is medically not a heart attack but a sign of increased risk. According to The British journal of Cardiology, chronic stable angina pectoris affects around 2 – 4% of the population in western countries and it is associated with an estimated annual risk of death and non-fatal myocardial infarction (MI) of 1–2% and 3% respectively. Based on the drug class, the angina pectoris treatment market is segmented into:

• Antiplatelet agents
• Beta-adrenergic blocking agents
• Calcium channel blockers
• Short & Long – acting Nitroglycerines
• Angiotensin-converting enzyme (ACE) inhibitors
• Anti-ischemic agents

Beta adrenergic blocking agents are the first line drug for angina pectoris treatment. Beta adrenergic blocking agents is one of the major drug classes in angina pectoris treatment market because these agents improve oxygen supply and demand balance by reducing heart rate and blood pressure, decreasing end systolic stress and contractility and prolonging diastole, allowing more coronary flow. The major factors assisting its growth are the efficiency, fast onset of action, accessibility to patients and high patient compliance.

Geography Segmentation Analysis

For the purpose of this study, the global angina pectoris market is categorized into:

• North America
• Europe
• Asia Pacific
• Rest of the World

North America was observed as the largest market for angina pectoris treatment in the base year 2015. According to American College of Cardiology, chronic angina pectoris affects over seven million North Americans every year and despite optimal pharmacological and interventional therapies, 32% of these patients remain symptomatic from coronary artery disease (CAD). Rising prevalence of angina pectoris, obesity in young population, sedentary lifestyle, and rising awareness related to early diagnosis of angina pectoris are major factors assisting the growth of North America angina pectoris treatment market. Europe is the second largest market followed by Asia Pacific, considering the prevalence rate Europe surpasses Asia Pacific and it’s considered as the most attractive region in angina pectoris therapeutics industry. However, Asia Pacific is estimated to pace at an exceptional growth rate due to rising prevalence of angina pectoris, high awareness related to cardiovascular diseases and developing healthcare infrastructure.